IQVIA (NYSE:IQV) Stock Rating Lowered by Wall Street Zen

IQVIA (NYSE:IQV) was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued on Saturday.

IQV has been the subject of several other reports. Baird R W upgraded shares of IQVIA from a “hold” rating to a “strong-buy” rating in a report on Wednesday, October 29th. Morgan Stanley boosted their price target on shares of IQVIA from $250.00 to $265.00 and gave the company an “overweight” rating in a research report on Monday, December 1st. JPMorgan Chase & Co. raised their price objective on shares of IQVIA from $177.00 to $255.00 and gave the stock an “overweight” rating in a report on Wednesday, October 29th. Stifel Nicolaus upped their target price on IQVIA from $234.00 to $254.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Finally, Hsbc Global Res raised IQVIA from a “hold” rating to a “strong-buy” rating in a research report on Thursday, October 9th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, IQVIA has a consensus rating of “Moderate Buy” and an average target price of $249.19.

IQVIA Trading Down 1.3%

IQV opened at $238.03 on Friday. IQVIA has a one year low of $134.65 and a one year high of $247.04. The company has a debt-to-equity ratio of 2.03, a current ratio of 0.70 and a quick ratio of 0.70. The business has a 50 day simple moving average of $227.30 and a two-hundred day simple moving average of $203.05. The firm has a market capitalization of $40.54 billion, a price-to-earnings ratio of 32.65, a PEG ratio of 2.45 and a beta of 1.36.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Tuesday, October 28th. The medical research company reported $3.00 earnings per share for the quarter, topping analysts’ consensus estimates of $2.98 by $0.02. The firm had revenue of $4.10 billion for the quarter, compared to analyst estimates of $4.07 billion. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The business’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same period last year, the company earned $2.84 EPS. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Analysts predict that IQVIA will post 10.84 EPS for the current year.

Insider Activity

In related news, insider Eric Sherbet sold 4,000 shares of the company’s stock in a transaction dated Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total value of $878,800.00. Following the transaction, the insider owned 27,108 shares in the company, valued at $5,955,627.60. The trade was a 12.86% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.60% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Verdence Capital Advisors LLC acquired a new position in shares of IQVIA during the 2nd quarter worth about $3,612,000. Amundi increased its stake in IQVIA by 46.3% in the second quarter. Amundi now owns 1,279,817 shares of the medical research company’s stock valued at $210,722,000 after purchasing an additional 405,250 shares during the last quarter. Act Two Investors LLC acquired a new stake in IQVIA during the second quarter worth approximately $26,528,000. Diversified Trust Co lifted its position in shares of IQVIA by 57.2% during the 3rd quarter. Diversified Trust Co now owns 42,579 shares of the medical research company’s stock worth $8,087,000 after buying an additional 15,487 shares during the last quarter. Finally, Patton Fund Management Inc. purchased a new position in shares of IQVIA in the 2nd quarter valued at $231,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.